Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 119Triple Negative Breast Neoplasms 8Inflammatory Breast Neoplasms 8Colorectal Neoplasms 8Ovarian Neoplasms 6Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Multiple Myeloma 2Melanoma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Women With Primary Breast Cancer 1Tracheal Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Solitary Pulmonary Nodule 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Fluorouracil × Breast × Clear all
NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Fudan University

Phase 3 Completed
2,079 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡